Hans-rudolf Brunner

Hans-rudolf Brunner's AcademicInfluence.com Rankings

Hans-rudolf Brunner

Philosophy

#4812

World Rank

#7464

Historical Rank

Logic

#2191

World Rank

#3127

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Hans-rudolf Brunner's Degrees

PhD Medicine University of Zurich
Doctorate Medicine University of Zurich

Why Is Hans-rudolf Brunner Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Hans-rudolf Brunner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial (2004) (2115)
Essential hypertension: renin and aldosterone, heart attack and stroke. (1972) (1101)
Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. (1972) (722)
Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. (1978) (613)
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial (2004) (612)
Endothelial function in chronic congestive heart failure. (1992) (581)
Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. (1972) (532)
Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor (1998) (416)
Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100): Comparison With Enalapril (2002) (389)
Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. (1979) (374)
Hypertension of Renal Origin: Evidence for Two Different Mechanisms (1971) (349)
Influence of oscillatory and unidirectional flow environments on the expression of endothelin and nitric oxide synthase in cultured endothelial cells. (1998) (342)
A SPECIFIC ORALLY ACTIVE INHIBITOR OF ANGIOTENSIN-CONVERTING ENZYME IN MAN (1977) (330)
Renal effects of selective cyclooxygenase‐2 inhibition in normotensive salt‐depleted subjects (1999) (329)
An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. (1974) (324)
Non-invasive estimate of the mechanical properties of peripheral arteries from ultrasonic and photoplethysmographic measurements. (1991) (291)
Angiotensin-Sodium Interaction in Blood Pressure Maintenance of Renal Hypertensive and Normotensive Rats (1973) (285)
Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. (1973) (264)
Antihypertensive Therapy with MK 4211: Angiotensin II‐Renin Relationships to Evaluate Efficacy of Converting Enzyme Blockade (1982) (261)
Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions (2001) (261)
Oral Administration of DuP 753, a Specific Angiotensin II Receptor Antagonist, to Normal Male Volunteers: Inhibition of Pressor Response to Exogenous Angiotensin I and II (1991) (253)
Angiotensin Converting Enzyme Inhibition in Patients with Congestive Heart Failure (1978) (252)
Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. (1973) (242)
Effects of modulators of the renin—angiotensin—aldosterone system on cough (1994) (238)
A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists (2013) (231)
Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. (2000) (224)
Synergistic effects of fluid shear stress and cyclic circumferential stretch on vascular endothelial cell morphology and cytoskeleton. (1995) (214)
Conduit artery compliance and distensibility are not necessarily reduced in hypertension. (1992) (213)
Malignant Hypertension Resulting from Deoxycorticosterone Acetate and Salt Excess: ROLE OF RENIN AND SODIUM IN VASCULAR CHANGES (1975) (211)
The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects. (1970) (208)
Angiotensin II vascular receptors: their avidity in relationship to sodium balance, the autonomic nervous system, and hypertension. (1972) (201)
Aliskiren: the first renin inhibitor for clinical treatment (2008) (198)
Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist (1992) (191)
Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. (1973) (191)
ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421". (1981) (190)
IMPROVEMENT OF CHRONIC CONGESTIVE HEART-FAILURE BY ORAL CAPTOPRIL (1979) (172)
Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. (2000) (171)
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout (2001) (160)
Isolated office hypertension: a prehypertensive state? (1996) (159)
Three new long‐acting converting‐enzyme inhibitors: Relationship between plasma converting‐enzyme activity and response to angiotensin I (1981) (157)
Isobaric compliance of the radial artery is increased in patients with essential hypertension (1993) (150)
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving Monotherapy (2006) (148)
Aldosterone Excretion: PHYSIOLOGICAL VARIATIONS IN MAN MEASURED BY RADIOIMMUNOASSAY OR DOUBLE‐ISOTOPE DILUTION (1972) (143)
Endogenous Angiotensin II Induces Atherosclerotic Plaque Vulnerability and Elicits a Th1 Response in ApoE−/− Mice (2004) (141)
Reciprocation of renin dependency with sodium volume dependency in renal hypertension. (1975) (125)
Reciprocal relation between renin dependency and sodium dependency in essential hypertension. (1976) (121)
Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. (1990) (120)
Angiotensin II receptor inhibition. A new therapeutic principle. (1996) (120)
Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. (2001) (120)
Renin as a risk factor in essential hypertension: more evidence. (1973) (115)
Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. (2012) (111)
Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. (2004) (107)
Proximal Sodium Reabsorption: An Independent Determinant of Blood Pressure Response to Salt (2000) (107)
Endothelial function in congestive heart failure. (1993) (104)
Pharmacokinetic-Pharmacodynamic Profile of Angiotensin II Receptor Antagonists (1997) (103)
Angiotensin II Receptor Blockade: Is There Truly a Benefit of Adding an ACE Inhibitor? (2003) (103)
The control of aldosterone secretion in normal and hypertensive man: abnormal renin-aldosterone patterns in low renin hypertension. (1972) (99)
Monitoring compliance in resistant hypertension: an important step in patient management. (2003) (99)
The neuropeptide Y Y1 receptor regulates leptin‐mediated control of energy homeostasis and reproductive functions (2002) (98)
Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing (2002) (94)
Ambulatory blood pressure recordings. Reproducibility and unpredictability. (1984) (93)
A device for subjecting vascular endothelial cells to both fluid shear stress and circumferential cyclic stretch (1994) (89)
VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk (2003) (88)
The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. (1997) (87)
Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial (2001) (86)
Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. (2000) (85)
In Vitro and in Vivo Characterization of the Activity of Telmisartan: An Insurmountable Angiotensin II Receptor Antagonist (2002) (83)
The renin axis and vasoconstriction volume analysis for understanding and treating renovascular and renal hypertension. (1975) (83)
Role of vasopressin, catecholamines, and plasma volume in hypertonic saline-induced hypertension. (1981) (79)
Antihypertensive Efficacy of Olmesartan Medoxomil and Candesartan Cilexetil Assessed by 24-Hour Ambulatory Blood Pressure Monitoring in Patients with Essential Hypertension (2003) (78)
Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes. (2002) (74)
The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview (2002) (74)
Renin Subgroups in Essential Hypertension: FURTHER ANALYSIS OF THEIR PATHOPHYSIOLOGICAL AND EPIDEMIOLOGICAL CHARACTERISTICS (1973) (73)
INNAPPROPRIATE RENIN SECRETION UNMASKED BY CAPTOPRIL (SQ 14 225) IN HYPERTENSION OF CHRONIC RENAL FAILURE (1978) (73)
NPY regulates catecholamine secretion from human adrenal chromaffin cells. (2001) (72)
Clinical Use of an Orally Acting Converting Enzyme Inhibitor: Captopril (1980) (72)
Spontaneous diameter oscillations of the radial artery in humans. (1993) (71)
Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients (1998) (70)
ARE SOME HYPERTENSIVE PATIENTS OVERTREATED? A Prospective Study of Ambulatory Blood Pressure Recording (1987) (70)
Blood sampling methodology is crucial for precise measurement of plasma catecholamines concentrations in mice (2003) (70)
Disappearance rate of catecholamines, total metanephrines, and neuropeptide Y from the plasma of patients after resection of pheochromocytoma. (2001) (69)
Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. (2001) (68)
Congestive heart failure in normotensive man. Haemodynamics, renin, and angiotensin II blockade. (1978) (68)
Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension. (1977) (67)
Confocal microscopy to analyze cytosolic and nuclear calcium in cultured vascular cells. (1994) (66)
Calcineurin Blockade Prevents Cardiac Mitogen-activated Protein Kinase Activation and Hypertrophy in Renovascular Hypertension* (2000) (65)
Flow-mediated arterial dilation is abnormal in congestive heart failure (1993) (64)
Increased insulin concentrations and glucose storage in neuropeptide Y Y1 receptor-deficient mice (2001) (63)
Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension (1995) (62)
Production and characterization of four anti-neuropeptide Y monoclonal antibodies. (1992) (61)
Aortic connexin43 is decreased during hypertension induced by inhibition of nitric oxide synthase. (1999) (61)
Evaluation of Arterial Compliance‐Pressure Curves Effect of Antihypertensive Drugs (1991) (60)
Unidirectional and oscillatory shear stress differentially modulate NOS III gene expression. (2000) (60)
Postischemic blood flow response in hypercholesterolemic patients. (1995) (59)
Is elevated plasma renin activity of prognostic importance in progressive systemic sclerosis? (1977) (59)
Tissue Factor Activity Is Upregulated in Human Endothelial Cells Exposed to Oscillatory Shear Stress (2002) (58)
Why Objective Monitoring of Compliance is Important in the Management of Hypertension. (2000) (58)
Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease. (2016) (57)
Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure. (2001) (56)
ACE inhibitors in renal disease. (1992) (56)
Role of prohormone convertases in pro-neuropeptide Y processing: coexpression and in vitro kinetic investigations. (1997) (56)
Plasma aldosterone-renin interrelationships in various forms of essential hypertension. Studies using a rapid assay of plasma aldosterone. (1973) (56)
Angiotensin II-induced cardiac hypertrophy is associated with different mitogen-activated protein kinase activation in normotensive and hypertensive mice. (2000) (55)
Fatal pancytopenia associated with the use of captopril. (1981) (54)
Hemodynamic and Humoral Effects of the New Renin Inhibitor Enalkiren in Normal Humans (1989) (52)
Long-term nitric oxide synthase inhibition and distensibility of carotid artery in intact rats. (1994) (52)
VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. (2004) (52)
Dose-response relationships following oral administration of DuP 753 to normal humans. (1991) (52)
Determination of cardiac contractility in awake unsedated mice with a fluid-filled catheter. (2004) (51)
Specific inhibition of the renin-angiotensin system: A key to understanding blood pressure regulation. (1974) (50)
Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects (1986) (50)
Practical solutions to the challenges of uncontrolled hypertension: a white paper (2008) (49)
Effect of magnesium deficiency on blood pressure and mechanical properties of rat carotid artery. (1999) (49)
Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects (1995) (47)
Pharmacokinetics and Pharmacodynamics of Pentopril, a New Angiotensin‐Converting‐Enzyme Inhibitor in Humans (1986) (47)
Sodium-induced elevation of blood pressure in the anephric state. (1980) (47)
Renal hemodynamic and tubular responses to salt in women using oral contraceptives. (2003) (46)
Dynamic non‐invasive measurements of arterial diameter and wall thickness (1992) (46)
Contributions of vascular tone and structure to elastic properties of a medium-sized artery. (1996) (45)
Angiotensin blockade for hypertension: a promise fulfilled (2002) (45)
Diabetes mellitus and vascular lesions. (1998) (44)
Simultaneous ipsilateral and contralateral measurements of vasomotion in conduit arteries of human upper limbs. (1995) (43)
Hemodynamic and Biochemical Consequences of Renin Inhibition by Infusion of CGP 38560A in Normal Volunteers (1989) (42)
Antihypertensive Efficacy of Olmesartan Medoxomil and Candesartan Cilexetil in Achieving 24-Hour Blood Pressure Reductions and Ambulatory Blood Pressure Goals (2011) (41)
Differential nitric oxide synthase activity in human platelets during normal pregnancy and pre-eclampsia. (1995) (41)
Effect of the Renin Response During Renin Inhibition: Oral Ro 42–5892 in Normal Humans (1991) (40)
Salt‐ And Angiotensin Ii‐Dependent Variations In Amiloride‐Sensitive Rectal Potential Difference In Mice (2000) (40)
Blood pressure and endocrine effects of single doses of CS‐866, a novel angiotensin II antagonist, in salt‐restricted hypertensive patients (1997) (38)
Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. (2001) (38)
Magnesium supplementation and deoxycorticosterone acetate--salt hypertension: effect on arterial mechanical properties and on activity of endothelin-1. (2002) (37)
Ambulatory blood pressure recording to identify hypertensive patients who truly need therapy. (1984) (37)
Norepinephrine and Renin Activity in Chronic Renal Failure: Evidence for Interacting Roles in Hemodialysis Hypertension (1981) (37)
Angiotensin Converting Enzyme Inhibition: Discrepancy Between Antihypertensive Effect and Suppression of Enzyme Activity (1989) (37)
Clinical experience with angiotensin II receptor antagonists. (1992) (37)
Converting enzyme inhibition in hypertensive emergencies. (1979) (36)
Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines. (1994) (36)
The Opposing Effects of Chronic Angiotensin‐Converting Enzyme Blockade by Captopril on the Responses to Exogenous Angiotensin II and Vasopressin vs. Norepinephrine in Rats (1981) (36)
Cardiac hypertrophy depends upon sleep blood pressure: a study in rats (2000) (36)
Time course changes of the mechanical properties of the carotid artery in renal hypertensive rats. (1997) (36)
Endotheliai function of the mesenteric arteriole and mechanical behaviour of the carotid artery in rats with insulin resistance and hypercholesterolaemia (1995) (36)
Renal segmental tubular response to salt during the normal menstrual cycle. (2002) (35)
Angiotensin II blockade in normal man: interaction of renin and sodium in maintaining blood pressure. (1977) (35)
Intraluminal pressure modulates the magnitude and the frequency of induced vasomotion in rat arteries. (1995) (34)
The return of increased blood pressure after discontinuation of antihypertensive treatment is associated with an impaired post-ischemic skin blood flow response (2001) (34)
Main objectives and new aspects of combination treatment of hypertension (1995) (33)
Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1‐receptor antagonist (2001) (33)
Renal sodium handling in acute and chronic salt loading/depletion protocols: the confounding influence of acute water loading (2000) (33)
Converting Enzyme Inhibition During Chronic Angiotensin II Infusion in Rats: Evidence Against a Nonangiotensin Mechanism (1981) (33)
Prevention of renal hypertension in the rat by neuropeptide Y. (1990) (32)
Effect of angiotensin converting enzyme inhibition on blood pressure, plasma renin activity and plasma aldosterone in essential hypertension. (1978) (32)
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy (2012) (32)
Endothelial dysfunction in chronic heart failure. Experimental and clinical studies. (1994) (31)
Mechanism of blood pressure reduction by teprotide (SQ 20881) in rats. (1978) (31)
Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relationships to immediate blood pressure response and control plasma renin activity. (1982) (31)
Clinical efficacy of olmesartan medoxomil. (2003) (31)
Angiotensin II Receptor Blockade in Normotensive Subjects A Direct Comparison of Three AT 1 Receptor Antagonists (1999) (31)
Blood pressure response to antihypertensive therapy: ambulatory versus office blood pressure readings. (1985) (31)
Renal and neurohormonal responses to increasing levels of lower body negative pressure in men. (2001) (30)
Renal Hemodynamic and Natriuretic Effects of Concomitant Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibition in Men (2002) (30)
Safety and Efficacy of Chronic Therapy with Captopril in Hypertensive Patients: An Update (1981) (30)
NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-α and IFN-γ in HUVEC (2003) (30)
Clinical efficacy and tolerability of olmesartan. (2004) (29)
Renin and aldosterone and the pathogenesis of hypertensive vascular damage. (1974) (29)
Effects of tyrosine infusion in normotensive and hypertensive rats. (1980) (29)
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy (2013) (29)
Non-invasive determination of arterial diameter and distensibility by echo-tracking techniques in hypertension (1992) (29)
Angiotensin II mediates catecholamine and neuropeptide Y secretion in human adrenal chromaffin cells through the AT1 receptor (2003) (29)
Dibasic cleavage site is required for sorting to the regulated secretory pathway for both pro‐ and neuropeptide Y (2002) (29)
Is the renin system necessary? (1980) (29)
The VALUE Trial (2005) (28)
Sustained 24‐hour blockade of the renin‐angiotensin system: A high dose of a long‐acting blocker is as effective as a lower dose combined with an angiotensin‐converting enzyme inhibitor (2005) (28)
Olmesartan medoxomil: current status of its use in monotherapy (2006) (28)
Vasopressin in Salt‐Induced Hypertension of Experimental Renal Insufficiency (1982) (28)
Neuropeptide Y expression, localization and cellular transducing effects in HUVEC (2005) (28)
The use of angiotensin-converting enzyme inhibitor in the diagnosis and treatment of hypertension. (1975) (28)
Trandolapril in hypertension: overview of a new angiotensin-converting enzyme inhibitor. (1992) (28)
Dietary magnesium intake can affect mechanical properties of rat carotid artery (2000) (27)
Age‐related changes of the mechanical properties of the carotid artery in spontaneously hypertensive rats (1997) (27)
Angiotensin II measurement with high‐affinity monoclonal antibodies (1988) (27)
Measurement of plasma endothelin-1 in experimental hypertension and in healthy subjects. (2003) (27)
Rapid Site-Directed Mutagenesis Using Two-PCR-Generated DNA Fragments Reproducing the Plasmid Template (2003) (26)
Response of plasma vasopressin to changes in extracellular volume and/or plasma osmolality in patients on maintenance hemodialysis. (1985) (26)
Population Pharmacokinetic-Pharmacodynamic Modelling of Angiotensin Receptor Blockade in Healthy Volunteers (2002) (25)
Compensatory up-regulation of angiotensin II subtype 1 receptors in alpha ENaC knockout heterozygous mice. (2001) (25)
Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans. (1997) (25)
Enhancement by diuretics of the antihypertensive action of long-term angiotensin converting enzyme blockade. (1980) (24)
Noninvasive Blood Pressure Monitoring at the Finger for Studying Short Lasting Pressor Responses in Man (1990) (24)
RHC 3659: a new orally active angiotensin converting enzyme inhibitor in normal volunteers. (1981) (24)
Antagonizing and Measurement: Approaches to Understanding of Hemodynamic Effects of Kinins (1992) (23)
Differences in the mechanical properties of the rat carotid artery in vivo, in situ, and in vitro. (1998) (23)
Suppression of Renin and Aldosterone by Clonidine. (1971) (23)
Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay. (1999) (22)
Neuropeptide Y Y2 receptor signalling mechanisms in the human glioblastoma cell line LN319 (2001) (22)
Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor. (1993) (21)
Increased response of brachial artery diameter to norepinephrine in hypertensive patients. (1988) (21)
Introduction to arterial compliance and function. (1992) (21)
Long-term treatment of hypertension in man by an orally active angiotensin-converting enzyme inhibitor. (1978) (21)
In-vitro response of plasma angiotensin converting enzyme to precursors and active forms of converting enzyme inhibitors (1984) (21)
Role of Reactive Hyperreninemia in Blood Pressure Changes Induced by Sodium Depletion in Patients with Refractory Hypertension (1981) (21)
A Comparative Study of the Effects of Oxprenolol Versus Propranolol in Essential Hypertension (1979) (21)
Evidence for a sodium-induced activation of central neurogenic mechanisms in one-kidney, one-clip renal hypertensive rats. (1982) (20)
Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers (1991) (20)
Role of vasoconstrictor systems in experimental glucocorticoid-hypertension in rats. (1983) (20)
Renal and hemodynamic effects of atrial natriuretic peptide in patients with cirrhosis. (1990) (20)
Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. (2000) (20)
Non‐invasive method for the assessment of non‐linear elastic properties and stress of forearm arteries in vivo (1992) (19)
Value of Different Clinical and Biochemical Correlates to Assess Angiotensin Converting Enzyme Inhibition (1994) (18)
ET-1 and NOS III gene expression regulation by plaque-free and plaque-prone hemodynamic conditions. (2003) (18)
Need for beta-blockade in hypertension reduced with long-term minoxidil. (1978) (17)
Effects of the new oral angiotensin converting enzyme inhibitor MK-421 in human hypertension. (1982) (17)
Comparison of the Angiotensin II Antagonist UP269–6 with the Angiotensin Converting Enzyme Inhibitor Enalapril in Normotensive Volunteers Challenged with Angiotensin I (1995) (17)
Isolated perfused mesenteric arteries of hypertensive and normotensive rats; response to norepinephrine, lysine vasopressin and angiotensin II. (1985) (16)
Endothelin inhibition as a biologic target for treating hypertension. (1998) (16)
High level expression of human neuropeptide Y receptors in mammalian cells infected with a recombinant vaccinia virus (1993) (16)
Vascular Damage in Hypertension (1975) (16)
Effect of Nadolol in Treatment of Hypertension (1979) (16)
Heterogeneous vascular response to vasopressin: radial artery versus forearm blood flow. (1997) (15)
NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-alpha and IFN-gamma in HUVEC. (2003) (15)
Accuracy, reproducibility and usefulness of ambulatory blood pressure recording obtained with the Remler system (1984) (14)
Salt-induced hypertension in chronic renal failure: evidence for a neurogenic mechanism. (1983) (14)
Clinical implications of renin in the hypertensive patient. (1975) (14)
Neuropeptide Y Prevents the Blood Pressure Fall Induced by Endotoxin in Conscious Rats With Adrenal Medullectomy (1988) (14)
Arterial dilatory reserve in congestive heart failure (1992) (14)
Non‐invasive measurement of internal diameter of peripheral arteries during the cardiac cycle (1988) (14)
Antihypertensive Efficacy of Ketanserin Alone or in Combination with a β‐Blocker or a Diuretic: The Swiss Ketanserin Study (1987) (13)
INHIBITORY EFFECT OF NEUROPEPTIDE Y ON STIMULATED RENIN SECRETION OF AWAKE RATS (1992) (13)
Is nurse-measured blood pressure a valid substitute for ambulatory blood pressure monitoring? (2000) (13)
Letter: Hypotensive effect of angiotensin-converting-enzyme inhibitor SQ 20,881. (1974) (13)
Mode of action of antihypertensive drugs (1966) (13)
Interactions between NPY and its receptor: assessment using anti-NPY antibodies (1994) (13)
Individualization of antihypertensive therapy. (1988) (13)
Effect of Ganglion Blockade with Pentolinium on Circulating Neuropeptide Y Levels in Conscious Rats (1988) (13)
Orally active angiotensin-converting enzyme inhibitor (SO 14,225) as a treatment for essential hypertension. (1979) (13)
Comparison in normal volunteers of three converting enzyme inhibitors: RHC 3659, MK 421 and captopril. (1982) (12)
The Renin-Angiotensin-Aldosterone System in Congestive Heart Failure (1983) (12)
Effects of the oral angiotensin-converting enzyme inhibitor MK-421 in human hypertension. (1981) (12)
Transient inhibition of angiotensinogen production in transgenic mice bearing an antisense angiotensinogen gene. (1995) (11)
Physiologic studies with saralasin in animals. (1979) (11)
Sympathetic nerve activity in conscious renal hypertensive rats treated with an angiotensin converting enzyme inhibitor or an angiotensin II antagonist (1995) (11)
Neuropeptide Y ( NPY ) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y 5 receptors (2000) (11)
[Local pulse pressure and regression of arterial wall hypertrophy during antihypertensive treatment. CELIMENE study. The Celiprolol Intima-Media Enalapril Efficacy study]. (2000) (10)
Is hyperuricaemia a predictor of cardiovascular risk (1999) (10)
Renal haemodynamic and protective effects of calcium antagonists in hypertension. (1995) (10)
Pseudo-Primary Aldosteronism, a Variant of Low Renin, Essential Hypertension? (1972) (10)
Angiotensin II blockade in normal man and patients with essential hypertension. Blood pressure effects depending on renin and sodium balance. (1976) (10)
Elastic behaviour of the carotid artery in intact spontaneously hypertensive rats. (1993) (10)
Remodelling of conduit arteries in hypertension: special emphasis on the mechanical and metabolic consequences of vascular hypertrophy. (1997) (10)
Differential Secretion of Catecholamine and Neuropeptide Y in Response to KCl from Mice Chromaffin Cells (2002) (10)
Dose-dependent lipid-lowering effects of simvastatin (MK-733) in the elderly (1989) (10)
Captopril in the treatment of hypertension. (1981) (10)
Angiotensin converting enzyme inhibition and renin inhibition (1989) (9)
Influence of sodium diet and deoxycorticosterone on the response to norepinephrine, lysine-vasopressin and angiotensin II of isolated perfused rat mesenteric arteries. (1983) (9)
Regionalized self-care hemodialysis. A solution to the increasing cost. (1983) (9)
Does protein binding modulate the effect of angiotensin II receptor antagonists? (2001) (8)
Angiotensin II receptor blockade prevents acute renal sodium retention induced by low levels of orthostatic stress. (2004) (8)
Vasopressin dilates the rat carotid artery by stimulating V1 receptors. (1998) (8)
Clinical hypertension and hypotension (1982) (8)
Effect of eight-day converting enzyme inhibition on ambulatory blood pressure recordings in normotensive volunteers. (1987) (8)
Aortic Connexin 43 Is Decreased During Hypertension Induced by Inhibition of Nitric Oxide Synthase (1999) (8)
DuP 532, an angiotensin II receptor antagonist: First administration and comparison with losartan (1997) (8)
[Autoregulation of the papillary vessels and their behavior as affected by halothane]. (1988) (8)
Converting enzyme inhibition during chronic angiotensin II infusion in rats: evidence against a non-angiotensin mechanism. (1980) (8)
Beta-adrenoceptor stimulation increases neuropeptide Y release from sympathetic nerves in intact rats (1995) (7)
Changes in treatment during and after hospitalization in patients taking drugs for cardiovascular diseases (1996) (7)
Vascular sympathetic nerve function in congestive heart failure. (1988) (7)
Effect of mental stress on the tone of a medium‐sized muscular artery (1992) (7)
Effects of intranasal administration of synthetic (4-28)human atrial natriuretic peptide to normal volunteers. (1989) (6)
Volume expansion enhances plasma endothelin-1. (2003) (6)
Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6. (2000) (6)
The renin-angiotensin system in hypertension: an update. (1990) (6)
The renin-angiotensin system and the heart: beyond 2000 (1996) (6)
[Prognostic value of the renin-angiotensin system in response to salt restriction and prognosis of alcoholic ascitic cirrhosis]. (1986) (6)
RATIONAL USE OF CAPTOPRIL (1979) (6)
Coronary and peripheral artery remodeling in patients undergoing PTCA: An intracoronary and transcutaneous ultrasound study (1999) (6)
[Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolemia]. (1990) (6)
Hemodynamic Effects of a Kinin Antagonist (1990) (6)
Ambulatory Blood Pressure Recording (1994) (6)
Vasopressin induces opposite changes in blood flow in the skin and the muscular circulation. (1998) (5)
Proceedings of the Symposium ‘Angiotensin AT1 Receptors: From Molecular Physiology to Therapeutics’: EXPERIENCE WITH ANGIOTENSIN II ANTAGONISTS IN HYPERTENSIVE PATIENTS (1996) (5)
Treatment of Hypertension with ACE Inhibitors as First Step: Pharmacologic and Clinical Considerations (1987) (5)
Evolution and hypertension: is the Renin system necessary? (2007) (5)
Objective monitoring of drug compliance: an important step in the management of hypertension resistant to drug therapy. (1999) (5)
Clinical experience with angiotensin II receptor antagonists. (1993) (5)
Valsartan in the treatment of hypertension (2005) (5)
Antihypertensive action of beta-adrenoceptor blockade and the renin-angiotensin system. (1979) (5)
The antihypertensive effect of beta-blockers. (1977) (4)
[Increased vascular sensitivity to nitroglycerin in patients with hypercholesterolemia and peripheral endothelial dysfunction]. (2008) (4)
Round Table: What blood pressure to measure? (1991) (4)
Vasopressin Blood Pressure Dependency after α-Adrenoceptor Blockade in Normotensive and Mineralocorticoid-Salt Hypertensive Rats (1982) (4)
Immersion and venous occlusion plethysmography in patients with idiopathic orthostatic hypotension. (1981) (4)
Validation of in-vitro data by in-vivo evidence: the example of angiotensin (1-7). (2006) (4)
Salt Subtraction in Patients on Maintenance Hemodialysis (1985) (4)
Renin and Aldosterone in the Etiology and Prognosis of Essential Hypertension: Their Relation to Vascular Complications (1972) (4)
THE VALSARTAN ANTIHYPERTENSIVE LONGTERM USE EVALUATION (VALUE) TRIAL: FINAL PATIENTS DEMOGRAPHICS (2000) (4)
TACHYCARDIA IS A STRONG PREDICTOR OF CARDIOVASCULAR EVENTS IN THE VALUE TRIAL: 6A.04 (2010) (4)
Interaction of the Sympathetic Nervous System with Vasopressin and Renin in the Maintenance of Blood Pressure in Rats (1982) (4)
Clinical Utility of Ambulatory Blood Pressure Monitoring in the Evaluation of Patients with Borderline Hypertension (1994) (4)
The role of hormones in congestive heart failure: new frontiers in therapy? (1982) (3)
Angiotensin II blockade in congestive heart failure. (1978) (3)
Antihypertensive efficacy and well-being during monotherapy and combination therapy with ketanserin. (1989) (3)
B027 Assessment of angiotensin II receptor blockade in humans using an in vitro binding assay: Comparison with the in vivo approach (1998) (3)
Arterial compliance and distensibility in spontaneously hypertensive rats (1992) (3)
[Angiotensin II inhibitors for the diagnosis and treatment of hypertension]. (1976) (3)
Saralasin in human hypertension: the early experience. (1979) (3)
Redistribution of regional blood flow after administration of saralasin in salt-depleted dogs. (1978) (3)
Pre- and Postsynaptic Effects of SKF64139, a Phenylethanolamine N‐Methyltransferase Inhibitor, in Conscious Normotensive Rats (1982) (3)
Effect of indomethacin and propranolol on the blood pressure and renin response to atriopeptin III in conscious rats (1987) (3)
Effect of Neuropeptide Y on Stimulated Renin Secretion a (1990) (3)
The Renin System in Hypertension (1987) (3)
Position Paper: Angiotensin-Converting Enzyme Blockade as a Therapeutic Modality (1981) (2)
PP.02.34: SAFETY OF LONG-TERM ENRICHED POTASSIUM SALT CONSUMPTION AND EFFECT ON BLOOD PRESSURE IN CHINESE (2015) (2)
[Inhibition of plasmatic renin activity by potassium]. (1967) (2)
Position of beta blockers in antihypertensive therapy. (1986) (2)
[Prevention of myocardial infarct?]. (1978) (2)
[Hyperreactivity of the humeral artery to noradrenaline in essential hypertension patients]. (1987) (2)
Letter: Renin profiling in hypertension. (1976) (2)
[Non invasive measurement of arterial compliance]. (1991) (2)
Salt subtraction in patients on maintenance hemodialysis. Efficacy and limitations. (1985) (2)
[Changes in medications acting on the cardiovascular system during hospitalization]. (2000) (2)
Angiotensin converting enzyme inhibition: a new therapeutic modality. (1981) (2)
Introduction: Position of beta blockers in antihypertensive therapy (1986) (2)
Hypertension, Vasopressors, and Susceptibility to Vascular Injury: Experimental and Clinical Studies (1981) (2)
Initial evaluation of the angiotensin converting enzyme inhibitor CGS 13945 in hypertensive patients (1985) (2)
Determination of renin-dependency and sodium-dependency in the three renin sub-groups of essential hypertension. (1976) (2)
Role of vasoactive peptides in blood pressure control. (1993) (2)
Clinical Application of Treatment with Angiotensin Receptor Antagonists (1994) (2)
[Physiopathology of left ventricular hypertrophy]. (1995) (2)
Position Paper: Vasoconstriction and Volume Factors in Renovascular Hypertension (1981) (2)
[Effect of atrial natriuretic factor on the hematocrit of patients in chronic hemodialysis]. (1987) (2)
Captopril: an oral angiotension converting enzyme inhibitor active in man. (1980) (2)
Postpropranolol vasodilation in adrenalectomized glucocorticoid hypertensive rats. (1987) (1)
OS 03-06 EFFECT OF LONG-TERM ENRICHED POTASSIUM SALT CONSUMPTION ON ALL CAUSES MORTALITY IN CHINESE LIVING IN NURSING HOUSES—A PRELIMINARY ANALYSIS (2016) (1)
INVESTIGATING THE CRITICAL SITUATION IN HYPERTENSION MANAGEMENT: DISPARITIES BETWEEN THE PERCEPTION AND REALITY OF THE BURDEN OF ‘CHALLENGING PATIENTS’ (SHARE SURVEY): PP.26.55 (2010) (1)
[Blood pressure lowering action and tolerance of ketanserin in mono- or combination therapy]. (1989) (1)
Lack of a Role of the Parasympathetic Nervous System in the Haemodynamic Response of Normotensive Rats to Atriopeptin III (1986) (1)
Prevention of vascular remodelling in cardiovascular disease. (1995) (1)
O-36: The orally active renin inhibitor SPP100 blocks the renin-angiotensin system in humans equally well as enalapril* (2001) (1)
The Position of β-Blockers in Antihypertensive Therapy (1979) (1)
P-453 *Program Revision (see p. 267A): Gender specific characteristics of 15,288 hypertensive patients at high coronary risk. The value trial (2001) (1)
[Cirrhotic ascites and the renin-angiotensin system]. (1980) (1)
A symposium : the role of angiotensin II receptor antagonists in the management of hypertension (1999) (1)
3. Effects of neuropeptide Y on renal hemodynamics and plasma renin activity of conscious normotensive rats (1991) (1)
Antihypertensive Agents: Mechanisms of Drug Action (2003) (1)
Pathophysiological concepts of renovascular hypertension. (1976) (1)
[Renin and sodium in blood pressure regulation]. (1974) (1)
Chapter 81 – Angiotensin II Receptor Blockers (2007) (1)
The value trial: patients demographics and progress report. (1999) (1)
INVESTIGATING THE CRITICAL SITUATION IN HYPERTENSION MANAGEMENT: IS PHYSICIAN INERTIA PUTTING PATIENTS AT INCREASED CARDIOVASCULAR RISK? (SHARE SURVEY): 4B.06 (2010) (1)
235 Influence of sodium intake on the renin-angiotensin system of rats with hypertension caused by chronic inhibition of nitric oxide synthesis (1993) (1)
O-28: Molecular basis for the insurmountable AT-1 receptor antagonism of telmisartan (2001) (1)
Discontinuation of chronic haemodialysis after control of arterial hypertension; long term follow-up. (1983) (1)
Simvastatin in the treatment of type II hyperlipoproteinemia in the elderly : a two-year experience (1991) (1)
Renal endothelin receptor type B upregulation in rats with low or high renin hypertension (2004) (1)
Early experience with angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors. (2001) (1)
Coronary and peripheral artery remodeling in patients undergoing PTCA: An intracoronary and transcutaneous ultrasound study. (1999) (1)
A8338 Effects of long-term enriched potassium salt consumption on premature death in Chinese living in nursing houses—preliminary analysis (2018) (1)
Neither hydralazine nor captopril significantly shifts carotid artery distensibility-pressure curves determined in intact spontaneously hypertensive rats. (1991) (1)
INVESTIGATING THE CRITICAL SITUATION IN HYPERTENSION MANAGEMENT: PHYSICIAN PERCEPTION AND USE OF THE ESH–ESC TREATMENT GUIDELINES (SHARE SURVEY): PP.20.306 (2010) (1)
[Treatment of refractory ascites by means of the LeVeen shunt]. (1981) (1)
Aldosterone Excretion PHYSIOLOGICAL VARIATIONS IN MAN (2005) (1)
Enhanced Urinary Kallikrein Excretion in Response to a Moderate Sodium Load in Genetically Hypertensive Rats (1988) (1)
DARK URINE AFTER EXTRACORPOREAL SHOCKWAVE LITHOTRIPSY (1987) (1)
108. Drug concentration-response relationships in normal volunteers after oral administration of DuP 753, an angiotensin II antagonist (1991) (1)
Under pressure: future prospects in hypertension management (2008) (0)
[Long-term minoxidil therapy: renin, aldosterone, noradrenaline and the need for beta blockers]. (1978) (0)
Effect of ANF on Urinary Kallikrein in Normal Man (1986) (0)
[Initial experiences with peritoneo-venous shunting by means of the Le Veen pressure-sensitive valve in the treatment of refractory ascites]. (1980) (0)
Introduction: moving towards the ideal angiotensin II receptor antagonist—building a consensus (1999) (0)
Characteristics of Renin Subgroups of Patients with Essential Hypertension. (1973) (0)
Preface: Swiss Hypertension Workshop on Vasopressin. (1986) (0)
[The ambulatory measure of tension profile with the Remler Portable Device (author's transl)]. (1981) (0)
Is Antihypertensive Therapy Expected to be Different in Postmenopausal Women (1994) (0)
PS-C37-5: NEW THERAPEUTIC PERSPECTIVES FOR BLOOD PRESSURE CONTROL: DEXFADROSTAT PHOSPHATE, A NOVEL ALDOSTERONE SYNTHASE INHIBITOR, IN PATIENTS WITH PRIMARY ALDOSTERONISM (2023) (0)
OR-53: Plasma immunoreactive endothelin-1 levels in hypertensive rats and human subjects (2003) (0)
B017: The valsartan antihypertensive longterm use evaluation (VALUE) trial: Final patients demographics (2000) (0)
Femoral atherosclerosis has a higher predictive value than carotid for detection of coronary heart disease (2000) (0)
Expression of concern (2018) (0)
HEART-FAILURE - DISCUSSION (1986) (0)
Transgenic mice with disrupted NPY Y1 receptor genes (1997) (0)
Comparison of the angiotensin II receptor blockade induced by tasosartan and its active metabolite enoltasosartan in healthy subjects. (1999) (0)
Determination of cardiac contractility in mice Comparison of two catheters and evaluation of the role of anesthesia (2002) (0)
The use of angiotensin II antagonists in combination treatment of hypertension (2006) (0)
ANTIHYPERTENSIVE ACTION OF P-ADRENOCEPTOR BLOCKADE AND THE RENIN-ANGIOTENSIN SYSTEM (2006) (0)
MULTIFACTOR REGULATION OF ALDOSTERONE (1965) (0)
Round table discussion: what blood pressure to measure? (1991) (0)
Angiotensin inhibitors for hypertension. (1980) (0)
[Causes favoring urinary infections and their treatment]. (1977) (0)
Individual variability to antihypertensive treatment and in organ complications (1995) (0)
Modulation of the tissue factor expression by various hemodynamic forces (2000) (0)
CYP11B2 Inhibitor Dexfadrostat Phosphate Suppresses the Aldosterone-to-Renin Ratio, an Indicator of Sodium Retention, in Healthy Volunteers. (2023) (0)
27 Cross-talk between intracellular calcium signalling pathways activated by neuropeptide Y and angiotensin II in human erythroleukaemia cells (1993) (0)
21 Biotinylation and fluorescein labelling of angiotensin II (1991) (0)
Shorter PFA-100-closure times in laparoscopic versus conventional hysterectomy are not caused by increased vasopressin levels. (2006) (0)
Human angiotensin I competes with two non‐thiol converting enzyme inhibitors (CGS 13934 & MK‐422) to inhibit the angiotensin‐converting enzyme activity of human plasma (1984) (0)
Measurement of activity of angiotensin converting enzyme in biological sample (1992) (0)
Rational Prescribing in Suboptimal Compliance (2002) (0)
The position of beta-blockers in antihypertensive therapy. Comparison with other antihypertensive agents. (1979) (0)
An easy approach to cardiovascular protection (1997) (0)
Ambulatory blood pressure recordings. Reproducibility and unpredictability. (1984) (0)
Systemtic and reg.ional hemodynamic effects of perindopril in exp.erimentaI heart fa.ilure (1993) (0)
The Use of SQ 20,881 Converting Enzyme Inhibitor (Teprotide) for Diagnostic Purposes in Hypertension (1980) (0)
Angiotensin-converting enzyme inhibitors: pathogenic and therapeutic implications for arterial hypertension. (1981) (0)
Hormonal, global, andregional haemodynamic responses toavascular antagonist ofvasopressin in patients withcongestive heart failure withand without hyponatraemia (1986) (0)
CLINICAL AND EXPERIMENTAL ASPECTS OF THE ANGIOTENSIN CONVERTING ENZYME IN BLOOD PRESSURE REGULATION (1983) (0)
Diabetic nephropathy in normotensive patients. Discussion (1990) (0)
47 The value of different humoral correlates in assessing the blockade of angiotensin II generation by the angiotensin converting enzyme inhibitor CS 622 (1993) (0)
Clinical trials of antihypertensive drugs (2004) (0)
A8Hypertension induced by inhibition of nitric oxide synthase: effects on renin and kinins (1995) (0)
[Arterial hypertension in chronic renal insufficiency]. (1978) (0)
EFFECTS OF SINGLE OR MULTIPLE DRUG THERAPIES ON CARDIOVASCULAR OUTCOMES IN HYPERTENSION: ANALYSIS OF DATA FROM THE VALUE TRIAL: 6C.04 (2011) (0)
[28] - Cytosolic and Nuclear Calcium Imaging by Confocal Microscopy (1996) (0)
Expression of concern (2018) (0)
Congestive heart failure in normotensive man Haemodynanics , renin , and angiotensin II blockade GUSTAVE (0)
[Noninvasive assessment of morphology and function of the great vessels]. (1995) (0)
Clinical application of orally active angiotensin converting enzyme inhibitors. (1983) (0)
[Usefulness of ambulatory registration of arterial pressure in therapeutic trials of antihypertensive agents]. (1985) (0)
OS 03-06 EFFECT OF LONG-TERM ENRICHED POTASSIUM SALT CONSUMPTION ON ALL CAUSES MORTALITY IN CHINESE LIVING IN NURSING HOUSES-A PRELIMINARY ANALYSIS. (2016) (0)
Angiotensin II‐induced cardiac hypertrophy is associated with associated with different mitogen‐activated protein kinase activation in normotensive and hypertensive mice (2000) (0)
Urinary aldosterone and sodium reabsorption in the distal nephron correlate with the activity of amiloride-sensitive sodium channels. (1999) (0)
[Interrelations between potassium, renin and aldosterone]. (1966) (0)
[Blood pressure recording in outpatient service: experience with the Sandoz Pressure System]. (1993) (0)
FIBROBLAST GROWTH FACTOR-2 MEDIATES ANGIOTENSIN II-INDUCED CARDIAC HYPERTROPHY IN HYPERTENSIVE MICE THROUGH MAPK ACTIVATION: 5B.8 (2000) (0)
[Is prevention of chronic renal insufficiency possible?]. (1976) (0)
Mediators in Septic Shock: The Renin-Angiotensin System (2019) (0)
P-225: Predictors of one year blood pressure control and treatment resistance in the value trial (2002) (0)
Comparative Cardiovascular Effects of Drugs Used for Hypertension (2012) (0)
179 Active dilation of the carotid artery induced by vasopressin in the intact rat (1993) (0)
J020: Endogenous lithium clearance to assess the salt-dependent changes in renal sodium handling: Effect of acute water loading (1998) (0)
Pathophysiology of proteinuria in diabetic glomerular disease. Discussion (1990) (0)
P-537: Pioglitazone blunts the blood pressure response to angiotensin II in insulin-resistant zucker rats (2003) (0)
Transportable device for intermittent compression to support a return transport of body fluid towards the heart, and using this apparatus, (1998) (0)
Measurement and analysis of arterial diameter-pressure curves: A novel method based on ultrasonic and photoplethysmographic techniques (1989) (0)
46 Inhibition of pressor responses to exogenous angiotensin II during an 8-day oral treatment of normal subjects with TCV116, an angiotensin II antagonist (1993) (0)
[Renin and sodium and the formation of vascular lesions in hypertension]. (1974) (0)
Calcium Antagonists and Renin-Angiotensin Inhibitors: New Antihypertensive Treatment Assets (1985) (0)
Introduction to the use of ambulatory blood pressure in therapeutic evaluations (1991) (0)
Characterization of endohelial function in patients with chronic heart failure (1991) (0)
[Definition and measurement values of acute respiratory insufficiency: ventilation, gas exchange and respiratory mechanics]. (1991) (0)
Role of Neuropeptide y in Endotoxemia (2019) (0)
Traitement chronique de l'hypertension arterielle par un inhibiteur de l'enzyme de conversion de l'angiotensine. [Chronic treatment of hypertension by an inhibitor of angiotensin converting enzyme] (1978) (0)
D012 Valsartan antihypertensive longterm use evaluation (the value study) (1998) (0)
Magnesium and mechanical properties of rat carotid artery. (2001) (0)
24H BLOCKADE OF THE RENIN-ANGIOTENSIN SYSTEM BY ONCE DAILY DOSES OF OLMESARTAN MEDOXOMIL GIVEN ALONE OR IN ASSOCIATION WITH AN ACE-INHIBITOR TO HEALTHY MEN: P2.347 (2004) (0)
[Discontinuation of chronic hemodialysis due to improved kidney function caused by the control of arterial hypertension]. (1979) (0)
Evaluation of the interaction of tasosartan and enoltasosartan with plasma proteins using an angiotensin II receptor binding assay. (1999) (0)
P-620: Pioglitazone stimulates renin and favors sodium retention and weight gain in healthy subjects (2003) (0)
Anti-hypertensive therapy by losartan. How effective is AT1 receptor blockade? (1995) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Hans-rudolf Brunner?

Hans-rudolf Brunner is affiliated with the following schools: